SOHO Egypt 2025 debuts with 2-day meeting in Cairo

The inaugural SOHO-EGYPT Meeting (November 5 to 6) was a joint session within NCI's BGO 2025 Congress ("Bridging Gaps in.

by SOHO Insider Editors
November 14, 2025

FDA approves ziftomenib for relapsed or refractory NMP1-mutated AML

Leah Sherwood November 14, 2025

The US Food and Drug Administration has approved the menin inhibitor ziftomenib for treatment of relapsed or refractory NMP1-mutated acute myeloid leukemia in adult patients who have no alternative treatment options.

Read More ➔

FDA grants 510(k) clearance to multiple myeloma diagnostic platform

Leah Sherwood November 13, 2025

The US Food and Drug Administration (FDA) granted 510(k) clearance to the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay, a first-of-its-kind automated platform for detecting and isotyping M-proteins in patients with multiple myeloma and related disorders.

Read More ➔

Multiple Myeloma. Multiple Myeloma disease blood test inmedical laboratory

IDP-023 demonstrates good safety, efficacy in relapsed or refractory myeloma

Leah Sherwood November 12, 2025

In a first-in-human study, IDP-023 demonstrated a promising safety and efficacy profile in patients with relapsed or refractory multiple myeloma, according to findings presented as a late-breaking poster by Dr. Krina Patel of the University of Texas MD Anderson Cancer Center at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Read More ➔

SOHO Young Investigator spotlight: Meet Maha Hameed, MD

SOHO Insider Editors November 11, 2025

As a resident physician who is fascinated by hematologic malignancies, Maha Hameed, MD, brings a distinctive combination of scientific intrigue and personal drive to her work in hematologic oncology.

Read More ➔

Natural killer T-cells show promise for ‘off-the-shelf’ cancer immunotherapy for NHL, ALL

Leah Sherwood November 10, 2025

Allogeneic natural killer T cells (NKTs) expressing CD19-specific chimeric antigen receptors (CARs) are well tolerated and can mediate objective responses in non-Hodgkin’s lymphoma (NHL) and relapsed acute B lymphoblastic leukemia (ALL) patients that relapsed following multiple salvage protocols, including commercial CAR-T products, according to a poster presentation presented at the Society for Immunotherapy of Cancer (SITC).

Read More ➔